Business
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
Approximately 600,000 people in the United States live with tardive dyskinesia (TD), and about 65% have not yet been diagnosed1-3The diagnosis rate can be
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"Approximately 600,000 people in the United States live with tardive dyskinesia (TD), and about 65% have not yet been diagnosed1-3The diagnosis rate can be improved by increasing routine TD screenings in people treated with antipsychotic medication4 SAN DIEGO, May 6, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living with TD during Tardive Dyskinesia Awareness Week, May 5-11. TD is a persistent, involuntary movement disorder associated with the use of antipsychotic medication that may be necessary to treat individuals living with mental illness, such as bipolar disorder, major depressive disorder, schizophrenia and schizoaffective disorder.1,5-7\n\n \n \n \n \n \n \n\n \nFor seven consecutive years, TD Awareness Week – which occurs each year during Mental Health Awareness Month – has brought together the mental health advocacy community and states across the country to recognize the approximately 600,000 people in the U.S. living with TD.1,2 This year, Neurocrine is joining participants of TD Awareness Week to conduct initiatives nationwide to decrease stigma, improve recognition and increase routine screenings, diagnosis and awareness of appropriate treatment of TD.\n\"TD Awareness Week increases dialogue around the physical, social and emotional consequences the uncontrollable movements of TD can have on individuals who are trying to manage their mental health,\" said Josie Cooper, Executive Director of the Movement Disorders Policy Coalition. \"It's important that we continue to work together to acknowledge and increase support for people living with TD and to ensure they receive the diagnosis and care they deserve.\"\nTD is a chronic condition that is unlikely to improve without treatment.1,4 The uncontrollable movements can affect one's ability to work, drive, walk, button a shirt or eat and drink and cause worry, frustration and self-consciousness.2,8-10 It is critical that people taking antipsychotic medication for mental illness be monitored by a healthcare provider for drug-induced movement disorders, such as TD.4,6 Routine screenings are essential for detection, proper diagnosis and appropriate management to help improve therapeutic outcomes.4\n\"The majority of people living with TD remain undiagnosed, reinforcing th...